TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study. In cases of doubt a pregnancy test should be performed. (NB -post menopausal women currently receiving hormone replacement are permissible)~* Acute myocardial infarction \< 12 h defined as:~  1. Angina or equivalent symptoms \> 20 min and~ 2. ST elevation in 2 contiguous ECG leads (= 2 mm precordial lead, = 1 mm limb lead). This ECG recording serves as baseline ECG, i.e. ECG I.~* Planned primary percutaneous coronary intervention~* The subject has given written informed, dated consent to participate in the study~Exclusion Criteria:~* Subjects not able to give informed consent~* Left Bundle Branch Block~* Thrombolytic therapy within 24 hours before randomization~* Oral anticoagulation with International Normalized Ratio (INR) \> 2~* Known platelets \< 100.000/µl or known hemorrhagic diathesis~* Stroke or Transient Ischemic Attack (TIA) within the past 6 months or any permanent residual neurological defect~* Evidence of an active gastrointestinal or urogenital bleeding~* Major surgery within 6 weeks~* History of allergic reaction to abciximab or eptifibatide or any component used in the study (including contrast media)~* Known severe renal (creatinine clearance \<30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN); isolated AST-elevation is not considered an exclusion criteria from study participation~* Severe concomitant disease with life expectation \< 1 year~* Subject has participated in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study.~* Subjects who will be inaccessible due to geographic or social factors during treatment or follow-up~* In France, a subject is neither affiliated with nor a beneficiary of a social security category.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abciximab (Type: ACTIVE_COMPARATOR): Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
- Eptifibatide (Type: EXPERIMENTAL): Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of mild persistent asthma as defined by NHLBI/WHO 97; for at least 6 months;~* FEV1 ³ 75% of predicted normal value;~* Positive response to the reversibility test to b2 agonist, defined as an increase \> 12% in the FEV1 measured 30 minutes following 2 puffs (2x100mg) of inhaled Salbutamol spray, or positive methacholine challenge (PC20\<8mg/ml or PD20\<1 mg) within the previous 6 months;~* Stable asthma. Asthma is defined stable if none of the following occurred during the last 14 days of the run-in period: diurnal variation of more than 20% in PEF on 2 consecutive days; use of four or more inhalations of b2 agonist per day on two consecutive days; need the use of oral corticosteroids;~Exclusion Criteria:~* COPD as defined by the ERS - Consensus Statement;~* Patients with more than 10 packs/year of cigarettes history and current smokers;~* History of near fatal asthma and/or admission in intensive care unit because of asthma;~* One severe exacerbation during the run-in period;~* Three or more courses of oral corticosteroids or hospitalisation for asthma during the previous 1 year;~* Patients treated with more than 500 mcg/day of beclomethasone or equivalent for more than 6 months in the previous last year;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy men or women,~* age 18 to 45 years inclusive;~* normal medical history and physical examination~* Women must have a negative pregnancy test.~Exclusion Criteria:~* travel to a cholera endemic area in the previous 5 years;~* abnormal stool pattern or regular use of laxatives;~* Currently active unstable or undiagnosed medical conditions~* current or recent antibiotic use;~* pregnancy or nursing;~* Previously received a licensed or investigational cholera vaccine~* History of cholera or enterotoxigenic E. coli infection~* History of Guillain-Barré Syndrome~* Received or plans to receive any other licensed vaccines, except for seasonal influenza~* Recipient of bone marrow or solid organ transplant~* Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders diagnosed or treated during the past 5 years~* Use of systemic chemotherapy in the previous 5 years prior to the study~* any immunosuppressive medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PXVX0200 Lot A (Type: EXPERIMENTAL): PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
- PXVX0200 Lot B (Type: EXPERIMENTAL): PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
- PXVX0200 Lot C (Type: EXPERIMENTAL): PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; \> 2x10\^8 CFU in a liquid suspension
- Placebo (Type: PLACEBO_COMPARATOR): Placebo physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. 11-13 years of age.~2. Signed informed consent form (both parent's \& daughter's signature).~3. Good health status.~4. Able to comply with trial protocol.~5. Plans to stay at current school for duration of study.~Exclusion Criteria:~1. Prior HPV vaccination~2. Pregnant or lactating or intends to become pregnant during study period.~3. Apparent moderate or severe acute illness.~4. Clinical history of bleeding disorder such as hemophilia, thrombocytopenia, or anticoagulant therapy.~5. Clinical history of impaired immune responsiveness, whether due to use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes.~6. Hypersensitivity to the active substances or to any of the excipients of the HPV vaccine, or such reactions to other vaccines received in the past.~7. Investigational drug or investigational vaccine administered during the period from 30 days before to 30 days after any dose of HPV vaccine.

- Gender: FEMALE
- Minimum Age: 11 Years
- Maximum Age: 13 Years
- Healthy Volunteers: t

Study Arms:
- 0,2,6 month vaccination schedule (Type: ACTIVE_COMPARATOR): None
- 0,3,9 month vaccination schedule (Type: ACTIVE_COMPARATOR): None
- 0,6,12 month vaccination schedule (Type: ACTIVE_COMPARATOR): None
- 0,12,24 month vaccination schedule (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of type 2 diabetes mellitus~* Hemoglobin A1c levels \>=7% and \<=10.5%~* taking a stable daily dose of metformin~* Body mass index (BMI) 25 to 45 kg/m2 except those of Asian descent who must have a BMI of 24 to 45 kg/m2~* Stable body weight~* Serum creatinine \<=1.5 mg/dL (132.6 umol/L) for men and \<=1.4 mg/dL (123.76 umol/L) for women~Exclusion Criteria:~* Patients must not have prior exposure or known contraindication or suspected hypersensitivity to canagliflozin (JNJ-28431754)~* Known contraindication or suspected hypersensitivity to sitagliptin or metformin~* A history of diabetic ketoacidosis or type 1 diabetes mellitus~* History of pancreas or beta-cell transplantation~* History of active proliferative diabetic retinopathy~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 50 mg daily (Type: EXPERIMENTAL): Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
- Canagliflozin 100 mg daily (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
- Canagliflozin 200 mg daily (Type: EXPERIMENTAL): Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
- Canagliflozin 300 mg daily (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
- Canagliflozin 300 mg twice daily (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
- Sitagliptin 100 mg daily (Type: ACTIVE_COMPARATOR): Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with documented HIV-1 infection~* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening~* Patient's HIV-1 plasma viral load at screening is \> 5,000 HIV-1 RNA copies/mL (assayed by RNA PCR standard specimen procedure)~* Patient's virus is sensitive to TDF and FTC~* Patient agrees not to start ART (antiretroviral treatment) before the baseline visit~Exclusion Criteria:~* Previous use of ANY ARV drug for ANY length of time~* Any documented evidence of NNRTI resistance associated mutations in patient's HIV~* Category C AIDS defining illness, except: stable Kaposi Sarcoma, wasting syndrome if not progressive~* Pneumocystis carinii pneumonia (PCP) that is considered not cured~* Active TB~* Allergy or hypersensitivity to study or background ARTs~* Specific grade 3 or 4 toxicity~* Kidney impairment: calculated creatinine clearance \<50 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Efavirenz (Type: ACTIVE_COMPARATOR): Efavirenz 600mg once daily for 96 weeks
- TMC278 (Type: EXPERIMENTAL): TMC278 25 mg tablet once daily for 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of congenital FXIII A-subunit deficiency (confirmed by genotyping at screening visit)~* Treatment with regular FXIII replacement therapy initiated at least 6 months prior to screening and one of the following : a documented history of at least one 1 treatment-requiring bleeding episode prior to initiation of regular replacement therapy or a documented family history of FXIII congenital deficiency (only for subjects on regular replacement therapy prior to screening)~* Documented history of at least two 2 bleeding episodes requiring treatment with FXIII containing blood products within the last 12 months prior to screening (only for subjects receiving on-demand treatment prior to screening)~Exclusion Criteria:~* Known neutralizing antibodies (inhibitors) towards FXIII~* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency~* Documented history of at least 2 treatment-requiring bleeding episodes per year during previous regular replacement therapy with FXIII containing blood products (fresh frozen plasma (FFP), plasma-derived FXIII (pd FXIII) and cryoprecipitate)~* Known or suspected allergy to trial product(s) or related products~* Planned major surgery during the trial period. Catheter, ports and dental extractions do not count as surgeries and will not exclude the subject~* Renal insufficiency defined as current dialysis therapy~* Any history of confirmed venous or arterial thrombo-embolic events

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rFXIII (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* To be considered for this study the patients should be aged between 18 to 65 years, need to suffer from schizophrenia and must be willing to participate.~Exclusion Criteria:~* Patients that suffer from psychiatric disorders other than schizophrenia including drug abuse and dependence, or medical conditions such as specific kidney, heart or thyroid problems, and patients with a known lack of response to drugs for schizophrenia will not be considered for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Age\>18 years~* Scheduled for hysterectomy with a fibroid uterus~* At least one intramural non-pedunculated, submucosal or subserous fibroid(\>2cm) or multiple small fibroids (uterine volume\>200cm3)~* Ability to understand and willingness to sign consent form~* Normal smear within 3 years~Exclusion criteria:~* Pregnant or lactating~* Contra indication to MRI~* Unable to tolerate supine position~* Diabetes and/or renal or hepatic impairment~* Contra indication to any of the study medications including gadolinium, MRI contrast

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): GnRH analogue-Zoladex
- 2 (Type: ACTIVE_COMPARATOR): GnRH antagonist plus GnRH analogue
- 3 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis~* Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low to medium doses of ICS (alone or in combination with LABA), used regularly as maintenance asthma therapy~* Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society \[ATS\]/European Respiratory Society \[ERS\] acceptability/repeatability criteria~* Pre-bronchodilator FEV1 of ≥50 to \<80% predicted normal value after withholding SABA ≥6 hours~* Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1 of ≥15%~* Only 2 reversibility testing attempts are allowed~Exclusion Criteria:~* Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)~* Oral corticosteroid use (any dose) within 6 weeks~* Received any marketed (eg, omalizumab, mepolizumab, reslizumab) or investigational biologic within 3 months or 5 half-lives, whichever is longer, or any other medication specifically prohibited by the protocol~* Current smokers, former smokers with \>10 pack-years history, or former smokers who stopped smoking \<6 months (including all forms of tobacco, e-cigarettes \[vaping\], and marijuana)~* Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)~* Historical or current evidence of a clinically significant disease~* Cancer not in complete remission for at least 5 years~* Hospitalized for psychiatric disorder or attempted suicide within 1 year~* Unable to abstain from protocol-defined prohibited medications during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- AS MDI (Type: EXPERIMENTAL): AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
- Proventil (Type: ACTIVE_COMPARATOR): Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects will have met the same inclusion criteria as MKC-TI-030~* Clinical diagnosis of URI with in 24 hrs prior to clinic visit and/or day of clinic visit~* At least 3 URI symptoms~Exclusion Criteria:~* Prior participation in MKC-TI-112~* MedHist, PE or lab findings of acute bacterial infection including but not limited to sputum prod., nasal/eye discharge, chest exam abnormalities, CXR findings of pneumonia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1: TI Inhalation Powder (Type: None): Technosphere® Insulin (TI) Inhalation Powder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be ambulatory~* Subject must have atteneded the 20010223 end-of-study visit and have completed all tests and procedures during the end-of-study visit~* signed informed consent must be obtained before any study-specific procedures~Exclusion Criteria:~* Experienced severe and/or serious adverse event which were thought to be related to denosumab administration during the 20010223 study.~* Developed grade 3 or 4 laboratory abnormalities based on Common Terminology Criteria for Adverse Events v3.0 during the 20010223 study which did not normalized upon follow up or did not have diagnosis or treatment.~* Newly diagnosed conditions such as hyper/hypo thyroidism, rheumatoid arthritis, other bone diseases, renal disease.~* Using therapies while participating in the 20010223 study such as oral bisphosphonates, calcitonin, oral strontium, SERMS, systemic glucocortiocosteriods.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG 162 (Type: EXPERIMENTAL): AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete